Patents by Inventor Jon A. Weidanz

Jon A. Weidanz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190071502
    Abstract: Disclosed herein are methods and compositions for targeting a complex comprising a non-classical HLA-I and a neoantigen in cancer. Further disclosed herein are antibodies that selectively bind to a complex comprising a non-classical HLA-I and a neoantigen, as well as methods of use thereof.
    Type: Application
    Filed: August 14, 2018
    Publication date: March 7, 2019
    Inventor: Jon WEIDANZ
  • Publication number: 20180086810
    Abstract: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 29, 2018
    Inventors: Jon A. Weidanz, Kimberlyn F. Card, Hing C. Wong
  • Publication number: 20160017031
    Abstract: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest.
    Type: Application
    Filed: May 27, 2015
    Publication date: January 21, 2016
    Inventor: Jon A. Weidanz
  • Publication number: 20140141455
    Abstract: Methods of assaying potency of a vaccine composition are provided. Said methods utilize a T cell receptor mimic that is reactive against a specific peptide/MHC complex. The potency of the vaccine is determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated antigen presenting cell.
    Type: Application
    Filed: October 14, 2013
    Publication date: May 22, 2014
    Inventor: Jon A. Weidanz
  • Publication number: 20140065708
    Abstract: A methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules, is disclosed. These antibodies may be utilized in therapeutic methods of mediating cell lysis.
    Type: Application
    Filed: October 15, 2013
    Publication date: March 6, 2014
    Inventor: Jon A. Weidanz
  • Publication number: 20130115191
    Abstract: Featured is T cell receptor complexes designed to redirect the immune system against various diseases. The T cell receptor complexes of the invention have been engineered to recognize target antigen in a functionally bispecific nature. Fusion protein complexes and protein conjugate complexes are comprised of high affinity antigen-specific TCR and biologically active proteins and/or effector molecules. Also featured is methods of production of T cell receptor fusion and conjugate complexes as well as therapeutic compositions for use of the complexes.
    Type: Application
    Filed: September 12, 2012
    Publication date: May 9, 2013
    Applicant: ALTOR BIOSCIENCE CORPORATION
    Inventors: Jon A. Weidanz, Kimberlyn F. Card, Hing C. Wong
  • Publication number: 20120230995
    Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.
    Type: Application
    Filed: December 22, 2011
    Publication date: September 13, 2012
    Applicant: Altor BioScience Corporation
    Inventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong
  • Publication number: 20120121577
    Abstract: Antibodies are produced that recognize peptides displayed in the context of MHC molecules and thus mimic the specificity of a T cell receptor (TCR). The antibodies are produced by immunizing a host with at least one peptide/MHC complex to elicit an immune response thereto. The desired antibodies can differentiate the peptide/MHC complex from the MHC molecule alone, the peptide alone, and a complex of MHC and irrelevant peptide. Finally, the desired antibodies are isolated.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 17, 2012
    Inventors: Jon A. Weidanz, Vaughan P. Wittman
  • Patent number: 8105830
    Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: January 31, 2012
    Assignee: Altor BioScience Corporation
    Inventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong
  • Publication number: 20110293623
    Abstract: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest.
    Type: Application
    Filed: June 7, 2011
    Publication date: December 1, 2011
    Inventor: Jon A. Weidanz
  • Publication number: 20090304679
    Abstract: The presently disclosed and claimed invention relates to a methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies may be utilized in therapeutic methods of mediating cell lysis.
    Type: Application
    Filed: February 27, 2009
    Publication date: December 10, 2009
    Inventor: Jon A. Weidanz
  • Publication number: 20090233318
    Abstract: The present invention is related to methods of assaying potency of a vaccine composition, wherein the potency is a pre-defined minimum level of potential biological activity for the vaccine composition. The method includes providing a vaccine composition and delivering same to an antigen presenting cell, wherein the vaccine composition is processed into peptides and the peptides are presented by MHC complexes on the cell surface. An agent, such as a T cell receptor mimic, that is reactive against a specific peptide/MHC complex is provided and reacted with the vaccine-treated antigen presenting cell, whereby the agent binds to the cell surface of the vaccine-treated antigen presenting cell if the specific peptide/MHC complex recognized by the agent is present on the cell surface. A density of the specific peptide/MHC complex on the surface of the vaccine-treated antigen presenting cell is measured by agent binding.
    Type: Application
    Filed: February 24, 2009
    Publication date: September 17, 2009
    Inventor: Jon A. Weidanz
  • Publication number: 20090226474
    Abstract: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest.
    Type: Application
    Filed: June 18, 2008
    Publication date: September 10, 2009
    Inventors: Jon A. Weidanz, William H. Hildebrand, Oriana Hawkins
  • Publication number: 20090075304
    Abstract: The present invention is related to methods of assaying potency of a vaccine composition, wherein the potency is a pre-defined minimum level of potential biological activity for the vaccine composition. The method includes providing a vaccine composition and delivering same to an antigen presenting cell, wherein the vaccine composition is processed into peptides and the peptides are presented by MHC complexes on the cell surface. An agent, such as a T cell receptor mimic, that is reactive against a specific peptide/MHC complex is provided and reacted with the vaccine-treated antigen presenting cell, whereby the agent binds to the cell surface of the vaccine-treated antigen presenting cell if the specific peptide/MHC complex recognized by the agent is present on the cell surface. A density of the specific peptide/MHC complex on the surface of the vaccine-treated antigen presenting cell is measured by agent binding.
    Type: Application
    Filed: August 22, 2008
    Publication date: March 19, 2009
    Inventors: Jon A. Weidanz, Francisca A. Neethling
  • Publication number: 20090042285
    Abstract: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest.
    Type: Application
    Filed: June 1, 2007
    Publication date: February 12, 2009
    Inventor: Jon A. Weidanz
  • Patent number: 7456263
    Abstract: The invention provides T-cell receptor (TCR) molecules comprising a V? chain and a V? chain that bind peptides derived from the p53 protein, preferably, the human p53 protein. The TCR molecules include both heterodimeric molecules and single chain molecules which specifically bind a sequence preferably spanning about amino acid positions 264-272 of the p53 protein displayed in the context of an HLA molecule, preferably, HLA-A2.1. Also disclosed are methods for making and using such TCR molecules. The invention has a wide spectrum of useful application including therapeutic uses and use in the detection of cells expressing p53 protein.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: November 25, 2008
    Inventors: Linda A. Sherman, Kimberlyn F. Card, Jon A. Weidanz, Hing C. Wong, Elizabeth L. Thomson
  • Publication number: 20080269113
    Abstract: The invention provides T-cell receptor (TCR) molecules comprising a V? chain and a V? chain that bind peptides derived from the p53 protein, preferably, the human p53 protein. The TCR molecules include both heterodimeric molecules and single chain molecules which specifically bind a sequence preferably spanning about amino acid positions 264-272 of the p53 protein displayed in the context of an HLA molecule, preferably, HLA-A2.1. Also disclosed are methods for making and using such TCR molecules. The invention has a wide spectrum of useful application including therapeutic uses and use in the detection of cells expressing p53 protein.
    Type: Application
    Filed: June 5, 2002
    Publication date: October 30, 2008
    Inventors: Linda A. Sherman, Kimberlyn F. Card, Jon A. Weidanz, Hing C. Wong, Elizabeth L. Thomson
  • Publication number: 20070116718
    Abstract: The present invention relates to novel fusion proteins comprising a bacteriophage coat protein and a single-chain T cell receptor and uses of such complexes. In one aspect, the invention relates to soluble fusion protein comprising a bacteriophage coat protein covalently linked to a single-chain T cell receptor which comprises a V-alpha chain covalently linked to a V-beta chain by a peptide linker sequence. The soluble fusion proteins of the invention are useful for a variety of applications including: 1) making a bacteriophage library for displaying single-chain T cell receptors for use in screens for identification and isolation of ligands that bind single-chain T cell receptors, and 2) methods for isolating soluble and fully functional single-chain T cell receptors from the fusion proteins.
    Type: Application
    Filed: June 15, 2006
    Publication date: May 24, 2007
    Inventors: Jon Weidanz, Kimberlyn Card, Hing Wong
  • Publication number: 20070092530
    Abstract: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest.
    Type: Application
    Filed: September 7, 2006
    Publication date: April 26, 2007
    Inventors: Jon Weidanz, Vaughan Wittman
  • Patent number: 7074904
    Abstract: The present invention relates to novel complexes of major histocompability complex (MHC) molecules and uses of such complexes. In particular, the invention relates to MHC fusion complexes that contain a MHC molecule with a peptide-binding groove and a presenting peptide covalently linked to the MHC protein. Fusion complexes of the invention are useful for a variety of applications including in vitro screens for identification and isolation of peptides that modulate activity of selected T cells, including peptides that are T cell receptor antagonists and partial agonists, methods of suppressing an immune response of a mammal and methods for inducing an immune response in a mammal.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: July 11, 2006
    Assignee: Altor Bioscience Corporation
    Inventors: Hing C. Wong, Peter R. Rhode, Jon A. Weidanz, Susan Grammer, Ana C. Edwards, Pierre-Andre Chavaillaz, Jin-An Jiao